Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q2 2018 Earnings Presentation
9 slides from Anika Therapeutics's earnings presentation, Jul 26, 2018
Slide 1: Second Quarter 2018 Earnings Call Presentation
Second Quarter 2018 Earnings Call Presentation July 26, 2018 NASDAQ: ANIK 0
Slide 2: Safe Harbor Statement
Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate mi
Slide 3: Future Perspective on Anika
Future Perspective on Anika Strategy Pipeline People Joseph Darling Performance President & Chief Executive Officer 2
Slide 4: Q2 2018 Financial Highlights
Q2 2018 Financial Highlights Q2 2018 PRODUCT REVENUE $30.5M PRODUCT GROSS MARGIN $0.68 $139M DILUTED EPS 8% INCREASE Q2 2017 OVER Q2 2018 73% Q2 2018 CASH & INVESTMENTS AT JUNE 30, 2018; NO DEBT • U.S. viscosupplement franchise grew 12% in Q2 • MONOVISC U.S. product and royalty revenue grew 42% in Q
Slide 5: CINGAL: Clinical Trial Update
CINGAL: Clinical Trial Update • CINGAL delivered greater pain reduction than the active-comparator • Difference at 26-weeks did not reach statistical significance • CINGAL has demonstrated safety and effectiveness in three controlled clinical studies • Total data package may present potential pathwa
Slide 6: Growing Portfolio of Regenerative Treatments: Bone Repair Treatment & HYALOFAST
Growing Portfolio of Regenerative Treatments: Bone Repair Treatment & HYALOFAST Bone Repair Treatment HYALOFAST • Received 510(k) clearance in Q4 2017 • Single-step, off the shelf, and cost effective solution to repair cartilage • Commercial launch expected in 2019 tissue • Injectable self-setting,
Slide 7: Growing Portfolio of Regenerative Treatments: Rotator Cuff Regenerative Therapy
Growing Portfolio of Regenerative Treatments: Rotator Cuff Regenerative Therapy • Unique therapy complementing Anika’s growing regenerative therapy portfolio • U.S. market opportunity of $150-200M • Over 650,000 rotator cuff procedures in U.S. alone with strong growth potential • Leverage Anika’s pr
Slide 8: Increased Focus on International Markets; New Operations Leadership
Focus on Improving Financial Performance and Operational Efficiency Increased Focus on International Markets • Increased involvement with international distributors with the goal of optimizing OUS performance • Hired industry veteran to evaluate and augment OUS business New Operations Leadership to
Slide 9: Q&A
Q&A Second Quarter 2018 Earnings Call Presentation July 26, 2018 NASDAQ: ANIK 8